Humoral-mediated immunity is transferred passively from mother to fetus during mammalian pregnancy. In humans, substances that pass from maternal blood to fetal blood must traverse the histological barrier, which consists of the syncytiotrophoblast, the stroma of the intravillous space, and the fetal capillaries. Although this barrier separates the blood in the maternal and fetal circulation, it is not a simple physical barrier. A wide range of substances is transferred actively or passively through the placenta to the fetus. Most low molecular mass compounds (< 500 Da) simply diffuse through the placental tissue interposed between the maternal and fetal circulation. Some low molecular weight substances, such as ions and amino acids, show unidirectional transfer across the placenta. Substances of very high molecular weight do not usually traverse the placenta, but there are a few exceptions such as immunoglobulin G (IgG) with a molecular mass of about 160 kDa.
The immunoglobulins in the fetus consist almost totally of maternal IgG and are transferred across the placenta by means of a specific receptor-mediated mechanism. IgG transport from mother to fetus begins at about week 16 of gestation and increases thereafter. Before week 16 of gestation, serum IgG concentrations of the fetus are < 8% of the average normal adult concentration. Between weeks 17 and 22 of gestation, fetal serum IgG concentrations range between approximately 10 and 20% of the adult value, and, after week 22 of gestation increase rapidly, reaching maternal serum IgG concentrations by 26 weeks of gestation and maintaining them until delivery (Gitlin, 1971) . The bulk of IgG is acquired by the fetus from the mother during the last 4 weeks of pregnancy, and fetal concentrations of IgG exceed maternal concentrations at full term. By the time of birth, fetal IgG1 concentration may exceed that of the mother. Fetal IgG2 concentration is often, but not always, lower than, and fetal IgG3 and IgG4 concentrations are equivalent to, maternal concentrations (Wang et al., 1970; Hay et al., 1971; Morell et al., 1971 Morell et al., , 1972 Virella et al., 1972; Schur et al., 1973; Chandra, 1976; Pitcher-Wilmott et al.,1980; Einhorn et al., 1987; Malek et al., 1994) . Newborns begin to produce IgG slowly and adult values of IgG are normally attained by 3 years of age.
Immunoglobulin class-specific transfer of maternal antibodies to the fetus occurs because maternal IgG, but not IgM or IgA, crosses selectively into the fetal circulation. On the basis of the observation that whole IgG molecules or Fc fragments of IgG pass into the fetal circulation more readily than F(ab')2 fragments (Brambell et al., 1960) , it has been hypothesized that IgG Fc receptors (FcγRs) on placental cells may be involved in the mechanisms responsible for IgG specific transfer across the placenta. There are three known subtypes of FcγRs: FcγRI, FcγRII, and FcγRIII, on human leukocytes. Several isoforms of each subtype on myeloid cells have been also reported (for review, see Huizinga et al., 1991; Ravetch et al., 1991) . This review focuses on the expression and localization of heterogeneous FcγRs, including leukocyte FcγRs and their isoforms, in human placental tissues, and possible mechanisms of FcγRs expressed on various cell components of placental villi for materno-fetal IgG transfer are discussed.
IgG-binding molecules in placenta
Various methods have been used to investigate IgG-binding molecules, such as FcγRs, in placenta. Most of them used the analysis of the binding of isolated human placental membrane extracts to radiolabelled human IgG or IgG-sensitized erythrocytes. Estimates of the affinity of monomeric IgG for receptors in placental membrane range from 4 × 10 6 to 4 × 10 8 mol l -1 and a total number of binding sites per mg placental membrane protein ranges from 2 × 10 12 to 2 × 10 14 (McNabb et al., 1976; Brown and Johnson, 1981; Niezgodka et al., 1981 ; Lubega, Cancer and Cardiovascular Diseases, Japan; and 2 Department of Obstetrics and Gynecology, Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Japan Transplacental transport of maternal immunoglobulin G (IgG) to the developing fetus is extremely important in the protection of the newborn from infection. (Balfour and Jones, 1978) . This heterogeneity was also demonstrated in IgG-binding molecules of placental membrane glycoprotein fraction extracted with lithium di-iodosalicylate. This fraction contained 26-29, 52-56 and 64-67 kDa proteins under reducing conditions that were precipitated with human IgG (Niedzgodka et al., 1981; Mikulska et al., 1987) . A 40 kDa FcγR has been purified using a mouse monoclonal antibody, designated as B1D6, which reacts with the apical aspect of trophoblast and the endothelium of the fetal stem vessels (Matre et al., 1984 (Matre et al., , 1989 . These results reflect the molecular heterogeneity of FcγRs in human placenta and indicate that heterogeneous expression of FcγRs may occur in the placenta, which is composed of a variety of cells, such as syncytiotrophoblasts, cytotrophoblasts, fetal endothelial cells and stromal cells, including immunocompetent cells (for review, see Saji et al., 1994; Simister and Story, 1997) .
Dynamics of immunoglobulins at the feto-maternal interface
The neonatal Fc receptor, designated as FcRn, has been identified in suckling rats (Rodewald and Kraehenbuhl, 1984; Simister and Rees, 1985; Simister and Mostov, 1989; Roberts et al., 1990) . This molecule, which mediates intestinal IgG transport, consists of two subunits: β 2 -microglobulin and a large subunit that resembles MHC class Ia chains. A human homologue of rodent FcRn has been isolated from human full-term placenta, and its unique distribution in human placenta has been determined (Story et al., 1994; Kristofferson and Matre, 1996; Leach et al., 1996; Simister et al., 1996) .
General characteristics of human FcγRs
The receptors for the Fc domain of IgG, FcγRs, are some of the most important structures in the immune system, providing an essential link between the humoral response and the cell-mediated immune system. FcγRs interact with immunoglobulin, and a variety of biological responses, including phagocytosis, endocytosis, antibody-dependent cellular cytotoxicity, release of inflammatory cytokines, and the enhancement of antigen presentation (Guyre et al., 1989; Simms et al., 1991) . Monoclonal antibodies and cDNA probes have provided details of the structure of FcγRs. FcγRs are members of an immunoglobulin superfamily, and three main classes, FcγRI, FcγRII and FcγRIII, generating at least 12 different isoforms, have been recognized to date.
Three distinct but closely related FcγR classes have been mapped to chromosome 1 and some of their characteristics are summarized (Table 1 ; Fig. 1 ) (Anderson and Looney, 1986; Ravetch and Kinet, 1991; van de Winkel and Capel, 1993) . FcγRI (CD64) is a 72 kDa glycoprotein with a high affinity for monomeric IgG that is constitutively expressed on monocytes-macrophages, and can be induced on neutrophils by interferon-γ stimulation (Perussia et al., 1983) . FcγRI possesses an extracellular region with three set immunoglobulin-like domains, a transmembrane region, and a cytoplasmic tail. A major difference in structure among FcγRI, FcγRII and FcγRIII is the third extracellular domain, which is found in FcγRI but not in FcγRII or FcγRIII. This unique structure may bind to monomeric IgG with a high association constant (Allen and Seed, 1989) . Three highly homologous genes, FcγRIA, IB and IC, have been identified and mapped to the long arm of chromosome 1, band q21.1 (de Wit et al., 1993 ). An important difference among the FcγRIA, IB and IC genes is located in the exon of the third extracellular domain, where stop codons are found in the FcγRIB and IC genes (van de Winkel et al., 1991; Ernst et al., 1992) . FcγRIA generates a single transcript encoding a molecule, FcγRIa, while FcγRIB yields two transcripts, a fulllength transcript (FcγRIb1), and one that lacks exon EC3 (FcγRIb2).
FcγRII (CD32) is a low-affinity receptor with a molecular mass of 40 kDa and is widely distributed on neutrophils, eosinophils, platelets, B cells and monocyte-derived cells. It is frequently expressed as the sole form of FcγR on cells.
Complementary DNA analysis has revealed the existence of multiple isoforms with similar extracellular domains, a transmembrane region, and cytoplasmic domains of variable length. Six isoforms, FcγRIIa1, FcγRIIa2, FcγRIIb1, FcγRIIb2, FcγRIIb3 and FcγRIIc, have been identified (Stuart et al., 1987; Hibbs et al., 1988; Stengelin et al., 1988; Clark et al., 1989; Seki, 1989) , encoded by a total of three genes, FcγRIIA, IIB and IIC, which are located on 1q23-24 (Brooks et al., 1989; Grundy et al., 1989; Cassel et al., 1993) . The products of FcγRIIA and IIB genes were found to differ in their signal peptides and cytoplasmic tails. Analysis of the gene structure showed the FcγRIIB and IIC genes to be highly homologous at their 5' ends, while FcγRIIA and IIC were very similar in the 3' regions. FcγRIIa, FcγRIIb and FcγRIIc are highly homologous in their extracellular domains, although FcγRIIa has two N-linked glycosylation sites, while FcγRIIb, and FcγRIIc have three. FcγRIIb differs considerably from FcγRIIa and FcγRIIc in the intracytoplasmic domain, sharing only the first eight amino acids.
FcγRIII (CD16) has a molecular mass between 50 and 80 kDa owing to extensive glycosylation. This low-affinity Fc receptor is expressed on neutrophils, eosinophils, natural killer (NK) cells, tissue macrophages and some T lymphocytes (Fleit et al., 1982; Kimberley et al., 1989) . Two genes, FcγRIIIA and FcγRIIIB, have been identified and localized on 1q23-24, approximately 200 kb apart from the FcγRII gene complex (Simmons and Seed, 1988; Peltz et al., 1989; Qiu et al., 1990) . The products of both genes encode proteins with extracellular regions consisting of two Ig-like domains. The FcγRIIIA gene encodes a transmembrane region with a 25 amino acid tail expressed in macrophages, NK cells, and some T cells. However, the FcγRIIIB gene product is linked to the outer leaflet of the plasma membrane via a phosphatidylinositol (PI)-glycan anchor, which is selectively expressed on polymorphonuclear cells (PMNs) (Ravetch and Perussia, 1989 Kurosaki and Ravetch, 1989; Lanier et al., 1989) . Expression of FcγRIII genes is highly regulated in a cell type-specific fashion, and the PI-linked FcγRIIIb isoform is expressed exclusively on PMNs. It is possible that FcγRIIIa transduces signals across the membrane independent of ligand-dependent engagement of FcγRIIa (Kimberley et al., 1990; Edberg et al., 1992; Hundt and Schmidt, 1992) . The presence of FcγRIIIa in the membrane depends on its co-expression with the FcεRI γ chain or the ζ chain of the CD3-TCR (T-cell receptor) complex.
Localization of FcγR family in human placenta

FcγRI
As monoclonal antibodies raised against the myeloid FcγRs, FcγRI, FcγRII, FcγRIII, have become available, a number of immunohistochemical studies have been performed on the placenta. The results of these studies on human term placenta are summarized (Table 2 ; Fig. 2 ). In these studies, careful evaluation of control staining has been done, because the affinity between immunoglobulins and their specific antigens is usually 84 F. Saji et al. (Kristoffersen et al., 1990; Kameda et al., 1991; Sedmak et al., 1991; Wainright and Holmes, 1993; Bright et al., 1994) . All of the reports are in clear agreement on the positive expression of FcγRI on Hofbauer cells. Since Hofbauer cells are mononuclear phagocytes, morphologically defined as macrophages by phagocytosis and by IgG interaction, the expression of FcγRI on Hofbauer cells is consistent with its known expression on monocytes and macrophages.
FcγRII
Several isoforms of the FcγRII molecule have been identified and preferential recognition of one or more of numerous isoforms may underlie the different recognition patterns of FcγRII monoclonal antibodies. Kristofferson et al. (1990) and Micklem et al. (1990) showed that FcγRII is present on the Hofbauer cells of placental stroma and on the endothelial cells of fetal vessels in placental tissues by immunohistochemistry using six different monoclonal antibodies raised against FcγRII (IV3, 2E1, CIKM3, CIKM5, 41H16 and KB61). Sedmak et al. (1991) and Kameda et al. (1991) obtained similar results, although some inconsistent findings were observed. Kameda et al. (1991) demonstrated positive staining of Hofbauer cells with IV3 in the first and third trimester placenta, and 2E1 reactive endothelial cells in the third, but not the first, trimester placenta. Kristofferson et al. (1990) , Micklem et al. (1990) and Sedmak et al. (1991) reported positive staining of placental macrophages and endothelium either by IV3 or 2E1 monoclonal antibody.
The negative staining of endothelial cells by IV3 is consistent with the findings of Stuart et al. (1989) . However, Stuart et al. (1989) revealed the positive IV3-staining of both Hofbauer cells and endothelium (Wainwright and Holmes, 1993) . None of the antibodies discriminate absolutely between FcγRIIa, b and c isoforms. In situ hybridization methods, which may help to account for the inconsistent findings of the immunohistochemical analysis, have not been used for placental FcγRs.
In the study of the mRNA expression of three distinct classes of FcγR in human placenta, transcripts of the FcγRII gene showed unique expression patterns during pregnancy. FcγRIIB mRNA increased markedly in the placenta in the second and third trimesters, while FcγRIIA or FcγRIIC, like FcγRI and FcγRIII, were transcribed consistently throughout pregnancy (Koyama et al., 1991) . It is perhaps significant that the FcγRIIB gene transcript is detected only after week 20 of gestation, since the maternal IgG transfer to the fetus is rapidly increased after week 22 of gestation (Gitlin, 1971) . Another interesting finding is the expression of FcγRII in the syncytiotrophoblasts of hydatidiform moles at mRNA and protein concentrations (Stuart et al. 1989) , since FcγRII is not detected on the trophoblast cells of the normal placenta. This exceptional expression of FcγRII on trophoblasts may be a consequence of tumourous transformation. et al., 1991; Wainwright and Holmes, 1993) . There are conflicting reports for 3G8 and Leu11b antibodies. Various studies on other monoclonal antibodies, GLB, Gran1, B73.1, YFC120.5 and GRAM1, gave similar results showing reactivity to Hofbauer cells but not to trophoblasts or endothelial cells in term placenta. Kristoffersen et al. (1990) reported that the antineutrophil FcγRIII antibody, 3G8, showed a strong positive reaction with trophoblasts and a weak positive reaction with stromal cells, and that Leu11b antibody showed a positive reaction with stromal cells, endothelial cells and trophoblasts. Sedmak et al. (1991) reported a strong positive reaction of 3G8 with trophoblasts and inflammatory cells. However, Kameda et al. (1991) reported that both 3G8 and Leu11b antibodies stained trophoblasts in the first and third trimester placenta, but no staining of macrophages and endothelial cells was observed. Wainwright and Holmes (1993) demonstrated positive staining of 3G8 to Hofbauer cells but no staining of trophoblasts and endothelial cells. Leu11b reacted with trophoblasts as well as Hofbauer cells and fetal vessel endothelium.
One explanation for the different staining patterns of 3G8 is the contamination of another antibody, probably against alkaline phosphatase. It should be noted that the early batches of 3G8 may have been contaminated with anti-placental alkaline phosphatase. Placental alkaline phosphatase is a glycophosphatidylinositol (GPI)-linked protein present in villous and extravillous trophoblast and in the amniochorion in term placenta (Sakiyama et al., 1979; Johnson and Molloy, 1983) . Leu11b reacted consistently with trophoblasts either in the first trimester placenta and term placenta by immunohistochemical analysis. However, Leu11b does not appear to identify typical FcγRIII components in trophoblasts. On immunoblots of trophoblast membrane, Leu11b detects a 74 kDa protein band that is different from a typical FcγRIII band detected by the other antibodies, although all are in the same range reported for the heterogeneously glycosylated FcγRIII (Wainwright and Holmes, 1993) . Nishikiori et al. (1993) prepared a trophoblastenriched fraction from term placenta, reconstructed the membrane protein in vitro and then used the trophoblast-enriched fraction for flow cytometry. Indirect immunofluorescence of the purified placental trophoblast fraction showed positive staining of 3G8 and Leu11b but negative staining of anti-FcγRI antibody (32.2) or anti-FcγRII antibody (IV3), indicating that the FcγRIII determinant for leukocyte-derived monoclonal antibodies is, at least, present on term trophoblasts. In fact, cDNA encoding FcγRIIIa has been amplified by reverse transcriptase polymerase chain reaction (PCR) from RNA obtained from term trophoblasts (Nishikiori et al., 1993) .
Two similar genes, FcγRIIIA and FcγRIIIB, encode membrane glycoproteins that are anchored by phosphatidylinositol glycan and membrane-spanning polypeptides, respectively. FcγRIII cDNA from total RNA of placental trophoblasts was cloned by reverse transcriptase-PCR, and DNA sequences were determined to characterize the placental trophoblast-specific FcγRIII isoform (Nishikiori et al. 1993) . The FcγRIII molecule on placental trophoblasts was encoded by the FcγRIIIA gene. These two distinct structures have been shown to have different susceptibilities against PI-specific phopholipase C (PLC), which can release proteins attached to the cell membrane by glycosyl-phosphatidylinositol anchors. In agreement with FcγRIII cDNA sequences derived from placental trophoblast mRNA, FcγRIII expressed on term placental trophoblasts is insensitive to PI-specific PLC. These findings are different from those reported for first trimester placental trophoblasts (Wainwright and Holmes, 1993) . Treatment of first trimester trophoblast membranes with PI-specific PLC removes most of the anti-FcγRIII (GLB Gran1) reactive proteins, indicating that they represent PI glycan-linked FcγRIIIb. Leu11b reactive proteins are unaffected. Further investigation of this hypothesis is required.
FcRn
An MHC class I-like FcR has been cloned from human placenta (Story et al., 1994) . Similar FcR in the neonatal rodent gut, FcRn (neonatal Fc receptor), transports maternal IgG from ingested milk in the gut to the bloodstream of newborn mammals (Israel et al., 1995) . The intestinal FcRn from neonatal rats is a heterodimer of an integral membrane glycoprotein similar to MHC class I a-chain and β 2 microglobulin (β 2 m) (Simister and Mostov, 1989) . Mouse FcRn was detected in the neonatal small intestine and the fetal yolk sac, two tissues involved in IgG transport (Ahouse et al., 1993) .
The DNA and predicted amino acid sequences of human FcRn are very similar to those of the neonatal rat and mouse intestinal FcRn. Human FcRn α-chain shares 65% predicted amino acid sequences with the rat homologue (Story et al., 1994) . FcRn protein is expressed on syncytiotrophoblasts in human term placenta (Kristoffersen and Matre, 1996; Leach et al., 1996; Simister et al., 1996) . FcRn is occasionally or weakly expressed on fetal vessel endothelium in placental tissues (Kristoffersen and Matre, 1996; Leach et al., 1996) but it is not expressed on Hofbauer cells in the placenta. Immunohistochemistry showed FcRn staining in a granular fashion throughout the cytoplasm of the syncytiotrophoblasts but no staining of the apical trophoblast membrane was observed (Kristoffersen and Matre, 1996) . When flow cytometry was used, the monoclonal antibody against FcRn did not stain the extracellular surface of the syncytiotrophoblast microvillous plasma membrane.
Like rodent FcRn, human FcRn binds IgG preferentially at low pH. The human FcRn expressing cell that transfected human FcRn cDNA bound the Fc fragment of IgG specifically at pH 6.0 but not at pH 7.5. The optimum binding of FcRn to IgG at low pH is reasonable for maternal milk IgG transport across the intestinal epithelium of rodents by FcRn. The pH in the duodenum and jejunum of neonatal rats is 6.0-6.5 (Rodewald, 1976) . However, human FcRn could not bind IgG at the surface of the syncytiotrophoblast or endothelium, because the pH of maternal and fetal blood is close to neutral and that of stroma is expected to be similar. The role of FcRn in humans requires further study.
IgG transfer and Fc receptors in placental tissues
The transfer of maternal IgG through the human placenta must cross the syncytiotrophoblasts, the stroma of the intravillous space and the fetal vessel endothelium. (Windebank et al., 1988; Leibson et al., 1990; Ting et al., 1992) . NK cell activation, mediated by FcγRIII crosslinkage, results in transcriptional activation of cytokines such as IFN-γ and TNF-α (Anegon et al., 1988; Cassatella et al., 1989) . These observations indicate that the FcγRIIIa molecule on trophoblasts may bind immune complexes or antibody-coated particles in the maternal circulation and may associate with the transcription of lymphokines or the triggering of cell-mediated immunity.
FcRn on trophoblasts may be involved in the transport of IgG across the materno-fetal barrier in humans (for review, see Simister and Story, 1997) . The hypothesis that FcRn is localized on syncytiotrophoblast is not supported by the immunohistochemical studies in which β 2 m, one of the two polypeptide chains of which FcRn comprises, was not detected in syncytiotrophoblast (Faulk and Temple, 1976) . In addition, although the finding that the optimum pH for the binding of FcRn to IgG is consistent with the previous observation that IgG binds optimally to placental membrane at pH 5.0-6.5 (Balfour and Jones, 1977; Watabe et al., 1980) , the intervillous spaces are not acidic but neutral. Furthermore, FcRn is not detected on syncytiotrophoblast apical plasma membrane (Kristoffersen and Matre, 1996) . A similar situation occurs in the rat fetal yolk sac, where FcRn appears to transport IgG without a pH gradient. In this tissue, it has been suggested that acidified endocytic vesicles transport IgG (Roberts et al., 1990) . A similar mechanism has been proposed for placental IgG transfer. IgG binds in endosomes to the receptor that transports it across the syncytiotrophoblast (Leach et al., 1991) . Further investigation, using functional assays in trophoblast model systems, into the role of FcRn in the transplacental transport of IgG is required.
Fetal endothelial cells in placenta express FcγRII and FcRn, although data on FcRn expression on endothelium is still conflicting. The receptor-mediated process of transcytosis was confirmed by Sooranna and Contractor (1991) using cultured cytotrophoblast cells grown on filters that allow access to the apical and basal surfaces of the cells. This experiment showed that IgG transport was specific and occurred primarily in the apical-to-basal direction. A similar apical-to-basal transport pattern of IgG has been demonstrated in epithelial cells transfected by isoforms of murine FcγRII cDNA (Hunziker and Mellman, 1989; Miettinen et al., 1989) . Murine FcγRIIB2 mediates efficient ligand internalization, delivery to lysosomes, and apical-tobasolateral transport of IgG. The cDNA of human FcγRIIB, which is more than 60% homologous to murine FcγRIIB2 in its cytoplasmic domain and 3'-untranslated region, was amplified by PCR and the transcription of the FcγRIIB gene increased markedly at week 20 of gestation (Koyama et al., 1991) . As maternal IgG transfer begins at mid-trimester, FcγRIIB in placenta is a candidate molecule for the unidirectional transfer of IgG in the placenta after mid-trimester. However, FcγRII has not been detected on trophoblast layers that are in contact with the maternal blood. Furthermore, there is no evidence of cooperation between FcγRII and FcγRIII or FcRn for intraplacental IgG transfer. Once again, further analysis is required.
